According to THE SAGE GROUP, High Restenosis Rates Following Endovascular Treatment of Infrapopliteal Disease Create a Significant Need for Improved Technologies
Recent research published by THE SAGE GROUP examines the challenges of infrapopliteal Peripheral Artery Disease (PAD) and incidence of restenosis.
- Recent research published by THE SAGE GROUP examines the challenges of infrapopliteal Peripheral Artery Disease (PAD) and incidence of restenosis.
- “It is difficult to reach strong conclusions regarding device superiority for endovascular treatment of infrapopliteal disease,” stated Mary L. Yost, President of THE SAGE GROUP.
- In addition to lesion length, these include primary efficacy end points, patient characteristics, lesion characteristics and morphology, as well as disease severity.
- “In infrapopliteal disease, we believe that new, more effective endovascular devices are needed to reduce restenosis and improve patient outcomes.